← Browse by Condition
Medical Condition

graft versus host disease

Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for graft versus host disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — graft versus host disease Clinical Trials

How many clinical trials are currently recruiting for graft versus host disease?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for graft versus host disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graft versus host disease?
graft versus host disease research spans Phase 1 (1 trial), Phase 2 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graft versus host disease clinical trial?
Eligibility criteria for graft versus host disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
4
Top Sponsors
Memorial Sloan Kettering Cancer Center 2 trials
Nantes University Hospital 1 trial
BioPhoenix Co., Ltd. 1 trial
University of Wisconsin, Madison 1 trial
University of Michigan Rogel Cancer Center 1 trial

Recruiting Clinical Trials

NCT06252870 Phase 2
Recruiting
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
Enrollment
82 pts
Location
France
Sponsor
Nantes University Hospital
View Trial →
NCT07246031 Phase 2
Recruiting
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
Enrollment
50 pts
Location
China
Sponsor
BioPhoenix Co., Ltd.
View Trial →
NCT06392711 Phase 1
Recruiting
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Enrollment
36 pts
Location
United States
Sponsor
University of Wisconsin, Madis...
View Trial →
NCT07566377 Phase 2
Recruiting
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Enrollment
71 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05675930 Phase 2
Recruiting
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Enrollment
44 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05866302
Recruiting
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
Enrollment
375 pts
Location
United States
Sponsor
University of Michigan Rogel C...
View Trial →
NCT06321003
Recruiting
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
Enrollment
200 pts
Location
Italy
Sponsor
University of Palermo
View Trial →

Related Conditions

hematologic malignancy (1) agvhd (1) haploidentical stem cell transplantation (1) cgvhd (1) xerostomia (1) sjogren s disease (1) acute myelogenous leukemia (1) acute lymphoblastic leukemia (1) myelodysplastic syndromes (1) non hodgkin lymphoma (1) hodgkin lymphoma (1) leukemia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology